The Oncology Institute names Mihir Shah as CFO; Dalgleish departs

Oncology Institute, Inc.

Scott Dalgleish ceases as CFO effective April 4, 2022; receives 3-month salary continuation and $47,750 bonus.
Mihir Shah appointed CFO, effective April 4, 2022; previously CFO at Commonwealth Care Alliance ($2B revenue).
Shah's annual base salary $405,000, target bonus 40%, and equity award of $453,085 (67% options, 33% RSUs).
Diona Simoneit, Chief Accounting Officer, appointed principal accounting officer effective April 1, 2022.
Press release issued April 4, 2022; departure unrelated to financial condition or controls.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Mihir Shah

Chief Financial Officer

TOI · Oncology Institute, Inc.

Effective: 2022-04-04
Filed: April 4, 2022, 7:59 PM ET

Effective as of April 4, 2022, the Company appointed Mihir Shah, to replace Mr. Dalgleish as the Company’s Chief Financial Officer

Departed

Scott Dalgleish

Chief Financial Officer

TOI · Oncology Institute, Inc.

Effective: 2022-04-04
Successor: Mihir Shah
Filed: April 4, 2022, 7:59 PM ET

Mr. Dalgleish will cease serving as the Company’s Chief Financial Officer effective April 4, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Mihir Shah was appointed as Chief Financial Officer at Oncology Institute, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

Effective as of April 4, 2022, the Company appointed Mihir Shah, to replace Mr. Dalgleish as the Company’s Chief Financial Officer

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Scott Dalgleish departed as Chief Financial Officer at Oncology Institute, Inc..

Action: ceased serving as
Role: Chief Financial Officer

Exact text from the filing

Mr. Dalgleish will cease serving as the Company’s Chief Financial Officer effective April 4, 2022.

View on SEC.gov

Oncology Institute, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-22-008192

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.